Cargando…

Astragaloside IV improves the pharmacokinetics of febuxostat in rats with hyperuricemic nephropathy by regulating urea metabolism in gut microbiota

Hyperuricemic nephropathy (HN) is a common clinical complication of hyperuricemia. The pathogenesis of HN is directly related to urea metabolism in the gut microbiota. Febuxostat, a potent xanthine oxidase inhibitor, is the first-line drug used for the treatment of hyperuricemia. However, there have...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Zhen Xiong, Tang, Xiao Hui, Jiang, Sheng Lu, Pang, Jia Qian, Xu, Yu Bin, Yuan, Dan Dan, Zhang, Ling Ling, Liu, Hui Min, Fan, Qing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807765/ https://www.ncbi.nlm.nih.gov/pubmed/36605404 http://dx.doi.org/10.3389/fphar.2022.1031509

Ejemplares similares

Pharmacologic Targeting of BET Proteins Attenuates Hyperuricemic Nephropathy in Rats
por: Xiong, Chongxiang, et al.
Publicado: (2021)

Febuxostat attenuates ER stress mediated kidney injury in a rat model of hyperuricemic nephropathy
por: He, Li, et al.
Publicado: (2017)

Comparison of the Effects of Allopurinol and Febuxostat on the Values of Triglycerides in Hyperuricemic Patients
por: Ziga-Smajic, Nermina, et al.
Publicado: (2020)

Astragaloside IV, as a potential anticancer agent
por: Xia, Dongqin, et al.
Publicado: (2023)

Insoluble Fiber in Barley Leaf Attenuates Hyperuricemic Nephropathy by Modulating Gut Microbiota and Short-Chain Fatty Acids
por: Li, Yongmei, et al.
Publicado: (2022)

Cardiovascular Safety of Febuxostat and Allopurinol in Hyperuricemic Patients With or Without Gout: A Network Meta-Analysis
por: Zhang, Shengzhao, et al.
Publicado: (2021)

Protective Effect and Possible Mechanisms of Astragaloside IV in Animal Models of Diabetic Nephropathy: A Preclinical Systematic Review and Meta-Analysis
por: Wang, Hong, et al.
Publicado: (2020)

Astragaloside IV Inhibits Galactose-Deficient IgA1 Secretion via miR-98-5p in Pediatric IgA Nephropathy
por: Liu, Caiqiong, et al.
Publicado: (2021)

Review on the protective mechanism of astragaloside IV against cardiovascular diseases
por: Yang, Chunkun, et al.
Publicado: (2023)

A Randomized Controlled Trial of the Effects of Febuxostat Therapy on Adipokines and Markers of Kidney Fibrosis in Asymptomatic Hyperuricemic Patients With Diabetic Nephropathy
por: Beddhu, Srinivasan, et al.
Publicado: (2016)

Effects of astragaloside IV on the pharmacokinetics of omeprazole in rats
por: Liu, Wei, et al.
Publicado: (2019)

Anti-Hyperuricemic and Nephroprotective Effects of Dihydroberberine in Potassium Oxonate- and Hypoxanthine-Induced Hyperuricemic Mice
por: Xu, Lieqiang, et al.
Publicado: (2021)

Astragaloside IV Improves Bleomycin-Induced Pulmonary Fibrosis in Rats by Attenuating Extracellular Matrix Deposition
por: Li, Liu-Cheng, et al.
Publicado: (2017)

Astragaloside IV Attenuates the Myocardial Injury Caused by Adriamycin by Inhibiting Autophagy
por: Luo, Li-Fei, et al.
Publicado: (2021)

Calcium Sensing Receptor-Related Pathway Contributes to Cardiac Injury and the Mechanism of Astragaloside IV on Cardioprotection
por: Lu, Meili, et al.
Publicado: (2018)

Gut Microbiota-Based Pharmacokinetics and the Antidepressant Mechanism of Paeoniflorin
por: Yu, Jin-Bo, et al.
Publicado: (2019)

The Mechanism Actions of Astragaloside IV Prevents the Progression of Hypertensive Heart Disease Based on Network Pharmacology and Experimental Pharmacology
por: Jing, Haoran, et al.
Publicado: (2021)

Astragaloside IV attenuates proteinuria in streptozotocin-induced diabetic nephropathy via the inhibition of endoplasmic reticulum stress
por: Wang, Zeng Si, et al.
Publicado: (2015)

Astragaloside IV Exerts Cardioprotection in Animal Models of Viral Myocarditis: A Preclinical Systematic Review and Meta-Analysis
por: Zhuang, Zhuang, et al.
Publicado: (2019)

Mangiferin Ameliorates Hyperuricemic Nephropathy Which Is Associated With Downregulation of AQP2 and Increased Urinary Uric Acid Excretion
por: Li, Xuechen, et al.
Publicado: (2020)

A comparative study of efficacy and safety of febuxostat and allopurinol in pyrazinamide-induced hyperuricemic tubercular patients
por: Pichholiya, Meenu, et al.
Publicado: (2016)

Astragaloside IV ameliorates diabetic nephropathy by modulating the mitochondrial quality control network
por: Liu, Xinhui, et al.
Publicado: (2017)

Astragaloside IV Attenuates Podocyte Apoptosis Mediated by Endoplasmic Reticulum Stress through Upregulating Sarco/Endoplasmic Reticulum Ca(2+)-ATPase 2 Expression in Diabetic Nephropathy
por: Guo, Hengjiang, et al.
Publicado: (2016)

Resveratrol Modulates the Gut Microbiota and Inflammation to Protect Against Diabetic Nephropathy in Mice
por: Cai, Ting-Ting, et al.
Publicado: (2020)

Pharmacokinetic study on the co-administration of abemaciclib and astragaloside IV in rats
por: Sun, Sen, et al.
Publicado: (2022)

Therapeutic Potential of Astragaloside IV Against Adriamycin-Induced Renal Damage in Rats via Ferroptosis
por: Qin, Lu-Yun, et al.
Publicado: (2022)

The Astragaloside IV Derivative LS-102 Ameliorates Obesity-Related Nephropathy
por: Li, Ziyu, et al.
Publicado: (2022)

Effect of febuxostat on blood pressure in hyperuricemic patients: A protocol for a systematic review and meta-analysis
por: Yao, Jia, et al.
Publicado: (2020)

Gut Microbiota-Regulated Pharmacokinetics of Berberine and Active Metabolites in Beagle Dogs After Oral Administration
por: Feng, Ru, et al.
Publicado: (2018)

Astragaloside IV Ameliorates Isoprenaline-Induced Cardiac Fibrosis in Mice via Modulating Gut Microbiota and Fecal Metabolites
por: Du, Xu-Qin, et al.
Publicado: (2022)

Elucidation of the binding mechanism of astragaloside IV derivative with human serum albumin and its cardiotoxicity in zebrafish embryos
por: Wu, You-Jiao, et al.
Publicado: (2022)

Effects of puerarin on the pharmacokinetics of astragaloside IV in rats and its potential mechanism
por: Zhang, Huan, et al.
Publicado: (2020)

Influence of astragaloside IV on pharmacokinetics of triptolide in rats and its potential mechanism
por: Gao, Jian, et al.
Publicado: (2020)

Natural Flavonoid Pectolinarigenin Alleviated Hyperuricemic Nephropathy via Suppressing TGFβ/SMAD3 and JAK2/STAT3 Signaling Pathways
por: Ren, Qian, et al.
Publicado: (2022)

Astragaloside IV Attenuated 3,4-Benzopyrene-Induced Abdominal Aortic Aneurysm by Ameliorating Macrophage-Mediated Inflammation
por: Wang, Jiaoni, et al.
Publicado: (2018)

Neuroprotective Effect of Astragaloside IV on Cerebral Ischemia/Reperfusion Injury Rats Through Sirt1/Mapt Pathway
por: Shi, Yi-Hua, et al.
Publicado: (2021)

Astragaloside IV attenuates ferroptosis after subarachnoid hemorrhage via Nrf2/HO-1 signaling pathway
por: Liu, Zhuanghua, et al.
Publicado: (2022)

A Mechanistic Exploratory Study on the Therapeutic Efficacy of Astragaloside IV Against Diabetic Retinopathy Revealed by Network Pharmacology
por: Zhao, Zhi-Hao, et al.
Publicado: (2022)

Identification of Hub Genes in Protective Effect of Astragaloside IV on Aconitine-Induced Cardiac Damage in Zebrafish Based on Bioinformatics Analysis
por: Wang, Mingzhu, et al.
Publicado: (2020)

Astragaloside IV Alleviates Tacrolimus-Induced Chronic Nephrotoxicity via p62-Keap1-Nrf2 Pathway
por: Gao, Ping, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_aahs07f5t91sv0nnikfgbq4nea